VRI 1
Latest Information Update: 02 Jul 2007
Price :
$50 *
At a glance
- Originator Cardiovascular Solutions
- Class Cardiovascular therapies
- Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 14 Jul 2004 This compound is still in active development - (BIO-2004)
- 04 Oct 2002 Preclinical trials in Vascular restenosis in Canada (unspecified route)